LFG
SRNE

LifePlan Financial Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

LifePlan Financial Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1K Buy
+50
New +$458 ﹤0.01% 565

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LifePlan Financial Group's SRNE Position: Q3 2020 in Review

LifePlan Financial Group opened a new position in Sorrento Therapeutics, Inc. (SRNE) in Q3 2020: 50 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #565 among its holdings.

209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • LifePlan Financial Group held 50 shares of Sorrento Therapeutics, Inc. worth $1K as of Q3 2020.
  • Sorrento Therapeutics, Inc. was a new LifePlan Financial Group position in Q3 2020.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of LifePlan Financial Group's portfolio in Q3 2020, its #565 holding.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on LifePlan Financial Group's 13F filing for Q3 2020, filed 30 Oct 2020.